Alembic Pharma Q1 Profit Jumps 21%

  Published 11 months ago

Alembic Pharma posted 21% YoY PBT growth in Q1 FY26, led by strong global generics and specialty therapy performance.

  • Revenue grew 9.54% YoY to Rs 1,710.72 crore, with EBITDA up 20% and margin stable at 17%.
  • US Generics rose 13% YoY to Rs 523 crore; Ex-US markets surged 21% to Rs 328 crore on new launches.
  • India Branded Business grew 5% YoY; three new products launched amid steady therapy segment performance.

You might like these

NGEL Q1 Profit Jumps 59% YoY

7 Coal Blocks Auctioned in 12th Round

Vidhi Specialty Q1 Profit Surges 45%

Landmark Expands KIA Showroom in Kolkata

ONGC & Pipavav Sign 5-Year Offshore Deal

India's Economy Gains Momentum in Q1

Nvidia Stock Rises Ahead of Earnings

News that matters the most ⚡